Results 11 to 20 of about 106,112 (301)

Tocilizumab [PDF]

Reactions Weekly, 2021
  +7 more sources

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report

Pediatric Rheumatology Online Journal, 2023
Background Tocilizumab is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist. Intravenous tocilizumab is considered an option for children with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis.
Francesca Burlo, Cristina Tumminelli, Serena Pastore, Gabriele Stocco, Debora Curci, Marianna Lucafò, Alberto Tommasini, Andrea Taddio   +7 more
doaj   +1 more source

LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification

Journal of Pharmaceutical Analysis, 2022
The quantitation of serum tocilizumab using liquid chromatography tandem-mass spectrometry (LC-MS/MS) method has not been widely applied in clinical settings because of its time-consuming and costly sample pretreatments.
Takashi Mochizuki, Kaito Shibata, Takafumi Naito, Kumiko Shimoyama, Noriyoshi Ogawa, Masato Maekawa, Junichi Kawakami   +6 more
doaj   +1 more source

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

Critical Care Explorations, 2021
Objectives:. To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. Design:. Observational multicenter cohort study. Setting:.
Russell M. Petrak, MD, Nicholas W. Van Hise, PharmD, Nathan C. Skorodin, PharmD, Robert M. Fliegelman, DO, Vishnu Chundi, MD, Vishal Didwania, MD, Alice Han, MD, Brian P. Harting, MD, David W. Hines, MD   +8 more
doaj   +1 more source

Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center

Revista de Investigación Clínica, 2022
Background: Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results. Objective: The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with ...
Bernardo A. Martinez-Guerra, Nereyda A. de-León-Cividanes, Karla M. Tamez-Torres, Carla M. Román-Montes, Sandra Rajme-López, Edgar Ortiz-Brizuela, Carlos A. Aguilar-Salinas, Juan Sierra-Madero, José Sifuentes-Osornio, Alfredo Ponce-de-León, María F. González-Lara   +10 more
doaj   +1 more source

Tocilizumab [PDF]

mAbs, 2009
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is ...
openaire   +2 more sources

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study [PDF]

, 2015
Objectives The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients.
Bathon, Joan M., Beaulieu, Andre D., Carlson, Timothy H., Codding, Christine E., Delles, Christian, Giles, Jon T., Lee, Janet S., McInnes, Iain B., Salmon, Jane E., Sattar, Naveed, Thompson, Liz   +10 more
core   +1 more source

Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study

Antibiotics, 2022
(1) Background: The efficacy of tocilizumab in COVID-19 has been doubted. The study aimed to investigate factors affecting disease stability and response to tocilizumab among severe COVID-19 patients.
Wael Hafez, Ahmed Abdelrahman
doaj   +1 more source

First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia

Frontiers in Medicine, 2020
Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19.Methods: Observational retrospective cohort ...
Omar Valenzuela, Omar Valenzuela, Sebastián Ibáñez, Sebastián Ibáñez, M. Cecilia Poli, M. Cecilia Poli, M. Cecilia Poli, Patricia Roessler, Patricia Roessler, Mabel Aylwin, Mabel Aylwin, Gigia Roizen, Gigia Roizen, Mirentxu Iruretagoyena, Mirentxu Iruretagoyena, Vivianne Agar, Vivianne Agar, Javiera Donoso, Javiera Donoso, Margarita Fierro, Margarita Fierro, José Montes, José Montes   +22 more
doaj   +1 more source

Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study

Life, 2023
Research Question: Does treatment with tocilizumab increase the risk of a fungal infection in critically ill patients with coronavirus-19? Background: Numerous therapies have been evaluated as possible treatments for coronavirus-2019 caused by severe ...
Barrett J. Burger, Sarenthia M. Epps, Victor M. Cardenas, Rajani Jagana, Nikhil K. Meena, William T. Atchley   +5 more
doaj   +1 more source